StockWatch
·
EUREKA FORBES · Q2 FY-2027 · THE VERDICT

Growth Reaccelerated, but Margins Are in Inflation's Grip

Revenue hit 15.1% YoY—proving the company's growth step-up is real. Yet gross margins collapsed 138 basis points as commodity costs surged, leaving Q3 margin recovery entirely dependent on whether mid-November price increases actually stick with consumers.

Q2 FY27 resultsEUREKAFORBEureka Forbes Ltd09 Nov 2026 · 6 min read
Revenue (Q2)

₹888.5 Cr

+15.1% YoY | +26.9% QoQ

Net Profit

₹74.1 Cr

+17.8% YoY | NPM 8.3%

Operating Profit Margin

12.9%

defended despite gross margin compression

Gross Margin

55.1%

−138 bps YoY to commodity inflation

Eureka Forbes delivered exactly what management promised on the prior call: a step-up in revenue growth from 12.7% to 15.1% YoY, broad-based across water purifiers, robotics, and emerging categories, with profitability intact at 8.3% net margin. But the quarter reveals a company under siege by commodity inflation. Gross margins fell 138 basis points to 55.1%, and management deliberately delayed price increases through the festive season to protect growth momentum. The result: flat H1 margins and a Q3 margin recovery now entirely contingent on whether 3–4% price increases stick post-Diwali. This is no longer a question of whether Eureka can grow; it's whether it can defend margin recovery while holding volume.

The core tension: growth vs. pricing power

The P&L tells a story of two competing forces. On one side, H1 revenue grew to ₹1,590 Cr, up 15.1% YoY from ₹1,381 Cr, confirming that the company's momentum is real and broad-based. Water purifiers alone grew over 30% sequentially, and emerging categories (robotics, water softeners, air purifiers) are accelerating at 2x the company average. On the other, gross margins shrank 138 bps to 55.1% as steel, motors, and materials costs surged with no abatement in sight. Management responded by taking cost out elsewhere: opex ratio fell 181 bps to 41.6% of revenue, enabling operating profit margin to hold at 12.9% and net margin to expand to 8.3% despite the gross margin collapse.

The gamble: by holding prices flat through Diwali, management bought growth and market share. Now it must prove that 3–4% price increases are both achievable without demand destruction (the bear case) and sufficient to recover margins (the bull case). The call offered no new demand elasticity data, and management acknowledged Q3 will be "transitionary" before Q4 recovery. That's code for margin volatility is coming.

Management's claims vs. what the numbers support

H1 FY27 revenue growth of 15.1% YoY (step-up from 12.7% prior year)

Delivered ₹1,590 Cr H1 revenue (15.1% YoY growth confirmed)

Supported

FY27 full-year EBITDA margins expected flat vs. FY26 (no expansion)

H1 margins flat at 12.2% YoY; on track if Q4 recovery hits target

Supported H1, Q3 at risk

Water Purifier sequential growth over 30% QoQ

Overall Q2 revenue +26.9% QoQ; water purifier cited as high-growth driver

Corroborated

Emerging categories growing 2x+ company average

Management detailed robotics, water softeners, air purifiers all accelerating

Plausible

PAT of ₹74.1 Cr (highest-ever quarterly)

Delivered ₹74.1 Cr PAT, +17.8% YoY

Supported

What changed on this call

Guidance updates and new priorities
  • Growth trajectory confirmed and accelerating (15.1% vs 12.7% prior year)

  • Margin guidance reaffirmed but phased: Q3 transitional, Q4 recovery expected

  • Emerging categories explicitly 2x growth; robotics ₹1,000 Cr FY30 target reaffirmed

  • New product innovation detailed (2-year, 4-year filter products; Aerogard air purifier launch with 6 SKUs)

Bull case vs. bear case

How the street is positioned

The stock trades at ₹365 (as of 2026-11-06), down 45.4% from its all-time high of ₹668.3 and below its 50-day and 200-day moving averages (₹367.4 and ₹448 respectively). This isn't a stock the market has gotten excited about post-result—it's a stock in a medium-term drawdown, albeit above its 52-week low of ₹300.1. RSI sits at 58.9 (neutral).

Ownership flows are mixed: FII trimmed by 41 bps to 13.25% in Q1, suggesting foreign fund caution on near-term margin recovery execution. Domestic institutional investors added 55 bps to 6.70%, signaling local conviction on the long-term growth story despite near-term margin volatility. Promoter stake remains steady at 62.55%.

The drawdown context matters: a 45% fall from ATH can mean a stock that was overpriced or one in genuine crisis. For Eureka, the data suggests the former. The company is growing faster (15.1% vs 12.7%), margins are under pressure but not broken (8.3% NPM defended), and margins are set to recover if pricing sticks. The stock's decline reflects the market repricing for near-term margin volatility and waiting for proof of pricing power. Foreign investors are waiting; domestic investors are buying the dip.

Risks, ranked by how much they should concern a holder

What could go wrong, and why it matters

Commodity inflation persists with no abatement

High

Gross margins already down 138 bps; further inflation forces deeper price increases or margin surrender. Management offers no visibility on commodity trajectory.

Mid-November pricing increases don't stick (demand elasticity higher than expected)

High

Q3 margin recovery is entirely contingent on price increases being accepted. If elasticity is high or consumer resistance emerges, Q4 margin target is missed and full-year guidance is cut.

Water purifier competitive intensity accelerates with new entrants

Medium

Management noted rising competition; Eureka's premium positioning and innovation can defend share, but pricing power erodes if intensity accelerates faster than expected.

Emerging categories fail to deliver at scale

Medium

Robotics, water softeners, and air purifiers are growing fast but still early-stage. Supply chain, product quality, and service delivery at higher volumes is unproven.

FII outflow accelerates if margin recovery misses

Low–Medium

FII already trimmed 41 bps; if Q3/Q4 results disappoint on margins, foreign fund selling could drive stock lower, cascading other selling.

What to watch next

Three concrete milestones that resolve the debate
  • 1 · Mid-November price increase execution and Q3 pre-result color

    Did the 3–4% price increases actually go through? Is there early feedback on demand impact (retail, e-commerce, channel feedback)? This is the highest-priority signal. Delayed guidance raise or Q3 guidance cut would be red flags.

  • 2 · Q3 FY27 results—margin trend

    The real test. Is Q3 margin the transitionary dip management expects, or deeper? If operating margin declines more than 50–100 bps from Q2, pricing has failed. If it holds or improves, the bull case gains traction.

  • 3 · Water purifier competitive dynamics and share data

    Management claimed market leadership; new competition is confirmed. Next quarterly call should offer transparency on market share trends, ASP realization, and new competitor positioning. Loss of share to discounters would signal a pricing power problem.

The bottom line

This was a steady execution quarter—growth reaccelerated, profitability defended—not a step-change. The company proved it can grow in a tough inflationary environment. What it hasn't yet proven is that it can recover margins while holding volume.

Eureka's guidance track record is strong (Q1 call targets all confirmed), and management's tone was measured and honest about challenges. That credibility matters.

The number to track from here is gross margin in Q3 and Q4. If it recovers to 55.5%+ by Q4, the 45% stock drawdown was an opportunity. If it stays below 55%, the market was right to reprice.

Informational and educational content only. Not investment advice.